Q-omics provides the consensus-scored RNASE10 profile across patient tissues and cancer cell-line models. RNASE10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNASE10 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RNASE10 RNA expression shows 13,754 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, HNSC, and TGCT as cancer lineages where RNASE10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE10 survival associations across molecular data types. RNASE10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE10 RNA expression–survival associations across cancer types. High RNASE10 expression shows unfavorable associations in LIHC, KICH, ACC, LGG, PAAD and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNASE10 RNA expression.
This table summarizes RNASE10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNASE10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE10 shows higher tumor expression in HNSC, KIRC, THCA, UCEC, BRCA and LUSC. The HNSC box plot shows higher RNASE10 RNA expression in tumor versus normal tissue (log2 FC = +2.558, t-test p < 0.001).
This table shows molecular features associated with RNASE10 in patient tissues and cancer cell lines. In patient samples, RNASE10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
